Hunter Associates Investment Management LLC Buys New Shares in Lumexa Imaging Holdings, Inc. $LMRI

Hunter Associates Investment Management LLC purchased a new stake in Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) in the first quarter, HoldingsChannel reports. The fund purchased 142,962 shares of the company’s stock, valued at approximately $1,231,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of LMRI. Assetmark Inc. bought a new position in shares of Lumexa Imaging during the 4th quarter worth about $36,000. Geode Capital Management LLC bought a new stake in shares of Lumexa Imaging in the fourth quarter valued at about $1,548,000. Seven Grand Managers LLC acquired a new stake in Lumexa Imaging during the fourth quarter worth about $11,942,000. Goldman Sachs Group Inc. acquired a new stake in Lumexa Imaging during the fourth quarter worth about $18,870,000. Finally, TD Asset Management Inc bought a new position in Lumexa Imaging during the fourth quarter valued at about $1,264,000.

Insider Transactions at Lumexa Imaging

In other Lumexa Imaging news, Director Brett Brodnax purchased 35,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The stock was purchased at an average price of $7.25 per share, with a total value of $253,750.00. Following the completion of the transaction, the director directly owned 62,027 shares of the company’s stock, valued at approximately $449,695.75. This trade represents a 129.50% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.70% of the stock is owned by company insiders.

Lumexa Imaging Stock Performance

NASDAQ:LMRI opened at $12.43 on Friday. The stock’s 50-day simple moving average is $9.17. The company has a market cap of $1.19 billion and a P/E ratio of -21.07. Lumexa Imaging Holdings, Inc. has a 52 week low of $6.45 and a 52 week high of $19.45. The company has a quick ratio of 1.40, a current ratio of 1.40 and a debt-to-equity ratio of 1.43.

Wall Street Analysts Forecast Growth

LMRI has been the subject of several recent research reports. Weiss Ratings raised Lumexa Imaging from a “sell (e)” rating to a “sell (d)” rating in a report on Thursday, June 25th. Wall Street Zen raised Lumexa Imaging from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. Finally, Barclays lowered their price objective on Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $16.00.

About Lumexa Imaging

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).